Life Scientist > Biotechnology

Strong growth continues for PanBio

06 March, 2002 by Pete Young

Diagnostic test company PanBio posted a first half sales jump of 49% to stay on track for a full year revenue target of $16.9 million.


Deloittes aims to flush out fast-moving biotechs

06 March, 2002 by Iain Scott

National accounting firm Deloittes has launched its Technology Fast 50 program for 2002.


BresaGen: stem cell debate won't affect our research

05 March, 2002 by Tanya Hollis

BresaGen has reassured investors its projects are not threatened by potential regulation of stem cell research in Australia.


Panbio pulls back from dendrimer joint venture

04 March, 2002 by Pete Young

A million-dollar collaboration between nano-drug company Starpharma and diagnostics specialist PanBio Ltd has come unstuck.


Cryosite poised for listing

04 March, 2002 by Daniella Goldberg

Cryosite, a Sydney-based biotechnology service company that stores frozen biological material, is going public.


Biota aims to reclaim position after flat half-year

04 March, 2002 by Tanya Hollis

Biota Holdings' much-hyped influenza drug, Relenza, failed to contribute revenue in an interim result that saw the company record a loss of $3.2 million.


Medical devices network takes shape

01 March, 2002 by Daniella Goldberg

A new network for the medical device industry is gearing up for launch.


Plant breeders to get access to genetic info

01 March, 2002 by Tanya Hollis

Plant breeders are expected to benefit from a joint venture between a Melbourne genetics company and the Victorian Government.


GroPep offloads IP to concentrate on protein pharma

01 March, 2002 by Tanya Hollis

South Australian drug discovery company GroPep (ASX:GRO) has begun selling off sections of its newly acquired intellectual property treasure chest.


Cash injection boosts Amrad R&D program

01 March, 2002 by Tanya Hollis

Drug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program.


R&D spend dominates BresaGen half-year

28 February, 2002 by Daniella Goldberg

Australian biotechnology company BresaGen's half-year results to December 2001 show an increase in revenue by 15 per cent, to $3,661,000, over the same period a year ago.


AgVic's genetic hens join the elites

28 February, 2002 by Tanya Hollis

Agriculture Victoria's 40-year bantamised hen project has entered the commercialisation phase, beginning a joint research deal with an elite international breeder.


Axon releases new drug discovery tool

28 February, 2002 by Tanya Hollis

A screening instrument that enables drug company technicians to run parallel tests has been released by Melbourne-based company Axon Instruments (ASX: AXN).


Shellfish gene helps Brisbane biotech

27 February, 2002 by Pete Young

Brisbane biotech business Xenome Ltd is moving closer to human trials with a pain-killing molecule derived from the venom of a marine shellfish.


MicroMedical's human heart trials imminent

26 February, 2002 by Tanya Hollis

Australia's first artificial hearts are to be implanted in human patients within weeks, according to the developer.


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd